Mission Therapeutics

Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs).

Mission Therapeutics is a platform of technologies for the development of drugs targeting enzymes involved in cancer and other diseases.

Mission Therapeutics was founded in 2011 by Steve Jackson. The company is headquartered in Cambridge, United Kingdom.

 

Mission Therapeutics has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

 

Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.

 

Mission Therapeutics is backed by Pfizer Ventures, Sofinnova Partners, Roche Venture Fund, Touchstone Innovations, SR One and others. The company raised $15m (£12M) in equity investment on Jul 06, 2020. This brings Mission's total funding to $145M to date.

 

 

  • Year founded: 2011
  • Funding Info: $145M over 4 Rounds (Latest Funding Type: Private Equity)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Cambridgeshire
  • Country: United Kingdom
Related businesses